Back to resources

Anthony Davies considers the possibility of a new CMC norm in this BPI article

February 14, 2020
Categories
Publications
In the News
CEO Anthony Davies sitting at head of conference table, gesturing expansively and smiling

In this Feb 2020 bioprocessintl.com article (click here), Dan Stanton talks to Dark Horse CEO Anthony Davies about what pattern Catalent's $315M acquisition of Masthercell might be foreshadowing.

Related Posts

Amanda Mack in November '24 issue of Cytotherapy

BPI: Planning, patient, and payer problems hurting gene therapy rollouts

BPI: Dark Horse bolsters CGT consulting outreach with BioTechLogic acquisition

CGT Insights publishes "Coming of age: an overview of the growing toolbox for gene editing..."

Join the Quarter Horse Newsletter

We’ll send you a quarterly newsletter all things DHC!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.